Next-Generation Sequencing-based Germline and Somatic Genetic Testing in Triple-negative Breast Cancer

Overview

For patients with triple negative breast cancer, implementation of genetic testing in decision making might impact both risk management for the patient and her family, but also, importantly, therapeutic management.

Identifying genetically predisposed subjects dictates risk-reducing strategies that may imply bilateral salpingo-oophorectomy and mastectomy or long term medical approaches. In the advanced setting, genetic testing can influence decision for medical therapy (e.g. use of platinum derivatives, poly-ADP ribose polymerase inhibitors (PARP inhibitors) in breast cancer patients with breast cancer susceptibility gene (BRCA) mutation.

The selection of patients for testing has long relied on the presence of a strong family history of breast and ovarian cancer. It is now clear that this criterion will result in substantial numbers of those with a BRCA mutation being missed.

Systematic large-scale genetic testing, simultaneously on germline and somatic tissues, is likely to improve decisional algorithms in patients with ovarian cancer. Feasibility of such approach in the clinical setting, in terms of a turnaround time compatible with clinical needs and sensitivity comparable if not superior to single-gene testing needs to be demonstrated before such diagnostic platforms can be routinely implemented in the diagnostic workflow. This is the scope of the present study.

Full Title of Study: “Evaluating the Feasibility of Next-Generation Sequencing – Based Germline and Somatic Genetic Testing in Triple-negative Breast Cancer. The PERSONA-breast Trial”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: December 31, 2020

Detailed Description

Systematic large-scale genetic testing, simultaneously on germline and somatic tissues, is likely to improve decisional algorithms in patients with triple negative breast cancers.

Feasibility of such approach in the clinical setting, in terms of a turnaround time compatible with clinical needs and sensitivity comparable if not superior to single-gene testing needs to be demonstrated before such diagnostc platforms can be routinely implemented in the diagnostic workflow.

Two platforms will be used during the course of the study. The Illumina TruSight Cancer Risk panel is a commercially validated targeted enrichment panel which targets 94 genes and 284 SNPs (Single Nucleotide Polymorphism) associated with a predisposition towards cancer.

The GermSom panel was developed at European Institute of Oncology (IEO) in collaboration with institutions within the Alleanza Contro il Cancro consortium and manufactured by Agilent Technologies. It includes 349 genes with an established function in the biology and/or pharmacological actionability of multiple solid tumors, including breast cancer. It includes all the genomic regions analysed in the Illumina Trusight panel, plus 32 additional regions associated with risk of multiple tumors.

Patients will receive detailed genetic characterization of their germline and their tumor. This will provide the best possible characterization of their risk of developing of a secondary malignancy and can be exploited to identify families at risk for hereditary cancer risk. Patients will also benefit from an increased likelihood of being treated with appropriate drugs and of receiving appropriate surgery.

Clinical Trial Outcome Measures

Primary Measures

  • Prevalence of mutations in breast cancer risk-associated genes
    • Time Frame: 3 months
    • Evaluate the prevalence of clinically relevant mutations in breast cancer risk-associated genes
  • Genetic test turnaround time
    • Time Frame: 6 months
    • Evaluate feasibility of genetic testing for clinical decision making
  • Percentage of informative specimens
    • Time Frame: 3 months
    • Percentage of patients with positive germline testing for target genes

Secondary Measures

  • Incidence of all other mutations
    • Time Frame: 3 months
    • Incidence of all other mutations
  • disease-free survival
    • Time Frame: 10 years
    • collection of disease associated events during follow-up
  • overall survival
    • Time Frame: 10 years
    • collection of death events during follow-up

Participating in This Clinical Trial

Inclusion Criteria

1. age between 18 and 60 years

2. has signed informed consent

3. histologically confirmed triple negative breast cancer (ER (Estrogen Receptors) < 1%, PgR (Progesterone Receptors) < 1%, HER2/neu negative (IHC 0, 1+ or 2+ FISH negative).

4. Stage I-III

5. Able to undergo surgery (primary or post-neoadjuvant)

6. Availability of surgical/bioptic material within 6 months from enrolment

Exclusion Criteria

  • unable or unwilling to receive genetic counselling

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 60 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • European Institute of Oncology
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Viviana E Galimberti, MD, Principal Investigator, IEO
  • Overall Contact(s)
    • Viviana E Galimberti, MD, +390257489717, viviana.galimberti@ieo.it

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.